Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,078 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS.
Loke J, McCarthy N, Jackson A, Siddique S, Hodgkinson A, Mason J, Crawley C, Gilleece M, Peniket A, Protheroe R, Salim R, Tholouli E, Wilson K, Andrew G, Dillon R, Khan N, Potter V, Krishnamurthy P, Craddock C, Freeman S. Loke J, et al. Among authors: jackson a. Blood Adv. 2023 Jul 25;7(14):3666-3676. doi: 10.1182/bloodadvances.2022009493. Blood Adv. 2023. PMID: 37058448 Free PMC article.
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, Andrew G, Nagra S, Malladi R, Peniket A, Gilleece M, Salim R, Tholouli E, Potter V, Crawley C, Wheatley K, Protheroe R, Vyas P, Hunter A, Parker A, Wilson K, Pavlu J, Byrne J, Dillon R, Khan N, McCarthy N, Freeman SD. Craddock C, et al. Among authors: jackson a. J Clin Oncol. 2021 Mar 1;39(7):768-778. doi: 10.1200/JCO.20.02308. Epub 2020 Dec 29. J Clin Oncol. 2021. PMID: 33373276 Free PMC article. Clinical Trial.
Reply to G. Gui et al.
Craddock C, Jackson A, Freeman SD. Craddock C, et al. Among authors: jackson a. J Clin Oncol. 2021 Jul 20;39(21):2416-2417. doi: 10.1200/JCO.21.00603. Epub 2021 May 5. J Clin Oncol. 2021. PMID: 33950696 No abstract available.
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial.
Malladi R, Ahmed I, McIlroy G, Dignan FL, Protheroe R, Jackson A, Moss P, Nunnick J, Siddique S, Bishop R, Elhaneid M, Hodgkinson A, Craddock C. Malladi R, et al. Among authors: jackson a. Bone Marrow Transplant. 2021 Dec;56(12):2948-2955. doi: 10.1038/s41409-021-01439-y. Epub 2021 Aug 26. Bone Marrow Transplant. 2021. PMID: 34446853 Clinical Trial.
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Fox CP, Ali AS, McIlroy G, Thust S, Martinez-Calle N, Jackson AE, Hopkins LM, Thomas CM, Kassam S, Wright J, Chaganti S, Smith J, Chau I, Culligan D, Linton KM, Collins GP, Ferreri AJM, Lewis D, Davies AJ, Johnson R, Auer DP, Cwynarski K. Fox CP, et al. Blood Adv. 2021 Oct 26;5(20):4073-4082. doi: 10.1182/bloodadvances.2021004779. Blood Adv. 2021. PMID: 34464973 Free PMC article. Clinical Trial.
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
Loke J, Metzner M, Boucher R, Jackson A, Hopkins L, Pavlu J, Tholouli E, Drummond M, Peniket A, Bishop R, Fox S, Vyas P, Craddock C. Loke J, et al. Among authors: jackson a. Br J Haematol. 2022 Jan;196(2):368-373. doi: 10.1111/bjh.17823. Epub 2021 Sep 6. Br J Haematol. 2022. PMID: 34490623 Free article.
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
Dillon R, Maycock S, Jackson A, Fox S, Freeman S, Craddock C, Thomas C, Homer E, Leahy J, Mamwell A, Potter N, Russell N, Wei A, Ommen HB, Hemmaway C, Knapper S, Billingham L. Dillon R, et al. Among authors: jackson a. BMC Cancer. 2022 Nov 14;22(1):1174. doi: 10.1186/s12885-022-10221-2. BMC Cancer. 2022. PMID: 36376888 Free PMC article.
ALL-RIC trial protocol: a comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission.
Marks DI, Castleton A, Olavarria E, Gilleece M, Fielding A, Mikhaeel G, Beasley M, Diez P, Jackson A, Hodgkinson A, Elhanied M, Chakraverty R. Marks DI, et al. Among authors: jackson a. BMJ Open. 2023 Jun 1;13(6):e067790. doi: 10.1136/bmjopen-2022-067790. BMJ Open. 2023. PMID: 37263700 Free PMC article.
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, Fox S, Ailts I, Dueck AC, Geyer HL, Mesa RA, Dunn WG, Nadezhdin E, Curto-Garcia N, Green A, Wilkins B, Coppell J, Laurie J, Garg M, Ewing J, Knapper S, Crowe J, Chen F, Koutsavlis I, Godfrey A, Arami S, Drummond M, Byrne J, Clark F, Mead-Harvey C, Baxter EJ, McMullin MF, Mead AJ. Harrison CN, et al. Among authors: jackson a. J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1. J Clin Oncol. 2023. PMID: 37126762 Free PMC article. Clinical Trial.
5,078 results